Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer

Journal of Clinical Oncology

Volumn 22, Issue 2, 2004, Pages 238-243

  Muler, Jeffrey H ^a   McGinn, Cornelius J ^a   Normolle, Daniel ^a   Lawrence, Theodore ^a   Brown, Diane ^a   Hejna, Gwen ^a   Zalupski, Mark M ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG TOLERABILITY; HUMAN; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; AGED; BIOASSAY; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; SURVIVAL; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 1342289781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.129     Document Type: Article

References (26)

1. Sohn TA, Yeo CJ, Cameron JL, et al: Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579, 2000
2. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006-2010, 1987
3. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776-782, 1999
4. Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705-1710, 1981
5. Kamthan AG, Morris JC, Dalton J, et al: Combined modality therapy for stage II and stage III pancreatic carcinoma. J Clin Oncol 15: 2920-2927, 1997
6. White RR, Hurwitz HI, Morse MA, et al: Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 8:758-765, 2001
7. Buris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
8. Casper ES, Green MR, Kelsen DP, et al: Phase Il trial of gemcitabine (2, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
9. Carmichael J, Fink U, Russell RC, et al: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73:101-105, 1996
10. Blackstock AW, Bernard SA, Richards F, et al: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17:2208-2212, 1999
11. Wolff RA, Evans DB, Gravel DM, et al: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7:2246-2253, 2001
12. Talamonti MS, Catalano PJ, Vaughn DJ, et al: Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 18:3384-3389, 2000
13. Lawrence TS, Chang EY, Hahn TM, et al: Radiosensitization of pancreatic cancer cells by 2′, 2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867-872, 1996
14. McGinn CJ, Zalupski MM, Shureiqi I, et al: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208, 2001
15. Philip PA, Zalupski MM, Vaitkevicius VK, et al: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92:569-577, 2001
16. Heinemann V, Wilke H, Mergenthaler HG, et al: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399-1403, 2000
17. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized, phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94:902-910, 2002
18. Symon Z, Davis M, McGinn CJ, et al: Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: From the laboratory to the clinic. Int J Radiat Oncol Biol Phys 53:140-145, 2002
19. Cheung K, Chappell R: Sequential designs for Phase I clinical trials with late onset toxicities. Biometrics 56:1177-1182, 2000
20. Normolle D, McGinn C, Zalupski M, et al: Designing dose escalation trials with late onset toxicities using the time-to-event continual reassessment method. Statistics in Medicine (submitted August, 2003)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
22. Ammori J, Colletti L, Zalupski MM, et al: Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 54:100, 2002 (suppl 1)
23. Albain K, Crowley J, Turrisi A, et al: Concurrent cisplatin, etoposide and chest radiotherapy in pathologic stage MIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454-3460, 2002
24. Adelstein D, Yi Li, Adams G, et al: An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98, 2003
25. Rose P, Bundy B, Watkins E, et al: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144-1153, 1999
26. Tempero M, Plunkett W, Ruiz van Haperen V, et al: Randomized phase II comparison of dose intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402-3408, 2003